Cryoplasty for the Treatment of Femoropopliteal Arterial Disease: Results of a Prospective, Multicenter Registry
|
|
- Edwina Richard
- 6 years ago
- Views:
Transcription
1 Clinical Studies Cryoplasty for the Treatment of Femoropopliteal Arterial Disease: Results of a Prospective, Multicenter Registry John Laird, MD, Michael R. Jaff, DO, Giancarlo Biamino, MD, Thomas McNamara, MD, Dierk Scheinert, MD, Patrick Zetterlund, MD, Elaine Moen, MD, and James D. Joye, DO PURPOSE: Despite suboptimal results, angioplasty of femoropopliteal arterial lesions has been a mainstay of endovascular therapy for many years. The recent introduction of cryoplasty marks a potential advance in the ability to effectively treat peripheral arterial atherosclerotic stenoses. This article presents the results of a prospective, multicenter trial that evaluated the efficacy of cryoplasty for femoropopliteal disease. MATERIALS AND METHODS: One hundred two patients with claudication and lesions of the superficial femoral and popliteal arteries of no greater than 10 cm were studied. All patients were treated with a primary strategy of stand-alone cryoplasty with use of the PolarCath cryoplasty system. The primary endpoints of the study were acute technical success and clinical patency at 9 months. Technical success was defined as the ability to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex ultrasound (US) imaging. Clinical patency was defined as freedom from target lesion revascularization within 9 months. Primary patency was defined by a duplex US systolic velocity ratio no greater than 2.0. RESULTS: A total of 102 patients were enrolled at 16 centers. Of those treated, 31% had diabetes and 31% were active cigarette smokers. The majority of the lesions were confined to the superficial femoral artery (84.3%) and 14.7% presented with total occlusions. The mean vessel diameter treated was 5.5 mm 0.5, the mean stenosis diameter was 87% 10%, and the mean lesion length was 4.7 cm 2.6. The technical success rate was 85.3% with a mean residual stenosis after cryoplasty of 11.2% 11.2% (P <.05 vs baseline). Clinical patency in this group was 82.2%, as only 16 patients required target lesion revascularization during the 9-month surveillance period. Primary patency determined by duplex US was 70.1%. CONCLUSIONS: Cryoplasty demonstrated a high degree of acute angiographic success and a low frequency of target lesion revascularization. The patency rate observed compares favorably to that previously documented with conventional angioplasty. J Vasc Interv Radiol 2005; 16: Abbreviations: ABI ankle-brachial index, PSV peak systolic velocity, SMC smooth muscle cell, SVR systolic velocity ratio, TASC TransAtlantic Inter-Society Consensus SINCE the development of percutaneous transluminal angioplasty 40 years ago, this technique has become the From the Washington Hospital Center, Division of Cardiology (J.L.), Washington, DC; Massachusetts General Hospital, Departments of Medicine & Surgery (M.R.J.), Boston; Universität Leipzig Herzzentrum, Department of Angiology (G.B., D.S.), Leipzig, Germany; University of California Los Angeles Medical Center, Department of Radiology (T.M.); Salinas Valley Memorial Hospital, Department of Medicine (P.Z.), Salinas; El Camino Hospital, Department of Medicine (J.D.J.), Mountain View, California; and St. Vincent s Hospital, Division of Cardiology (E.M.), Indianapolis, Indiana. Received August 11, 2004; revision requested February 12, mainstay of endovascular therapy for intermittent claudication of the lower extremities (1). However, despite 2005; final revision received March 5; accepted March 8. From the 2004 SIR Annual Meeting. Address correspondence to J.D.J.; The Cardiovascular Institute, 2660 Grant Rd, Mountain View, CA 94040; jimjoye@aol.com J.D.J. is a shareholder and has intellectual property in Cryovascular Systems Inc. None of the other authors have identified a conflict of interest. SIR, 2005 DOI: /01.RVI E widespread practice, angioplasty continues to be limited acutely by arterial dissection and recoil and by suboptimal long-term patency rates, especially in more challenging lesions. Although some degree of acute dissection is inherent in most angioplasty procedures, a recent analysis demonstrated greater than desired dissection in a significant number of treated vessels (2). In addition, a contemporary metaanalysis of femoropopliteal angioplasty has demonstrated a 1-year patency rate of 59% among multiple lesion subsets (3). Stent implantation at the time of angioplasty has been used in an effort to improve endovascular outcomes. 1067
2 1068 Femoropopliteal Cryoplasty: Multicenter Midterm Results August 2005 JVIR Stent placement has improved the acute technical results of angioplasty by eliminating vascular recoil and resolving arterial dissection (4). Because of the aggressive neointimal proliferation, stent implantation of femoropopliteal arteries has done little to extend the durability of endovascular interventions, limiting their application to a bailout indication (5 8). Endovascular cryotherapy, also known as cryoplasty, represents a new method of peripheral vascular intervention. Cryoplasty combines the dilation force of angioplasty with the simultaneous delivery of cold thermal energy to the arterial wall. Both mechanisms are achieved by filling the catheter with nitrous oxide instead of the usual contrast material/saline solution mixture. Cryotherapy has been shown to biologically alter the behavior of arterial cellular components in a manner that results in a benign healing process (9). In particular, collagen fibers are unperturbed and therefore maintain the architectural integrity of the artery, whereas elastin fibers undergo a morphologic change that may limit vascular recoil. In addition, cryotherapy is capable of inducing apoptosis in smooth muscle cells (SMCs) and other cell lines that participate in the restenosis process (10). Early clinical reports of cryoplasty for femoropopliteal disease have shown encouraging results (11). The purpose of this study was to evaluate the safety and efficacy of femoropopliteal cryoplasty in a prospective multicenter registry. MATERIALS AND METHODS Patient Group The study was approved by the United States Food and Drug Administration. One hundred two patients with intermittent claudication caused by femoropopliteal arterial disease were enrolled in a prospective, nonrandomized, multicenter registry. Patients were eligible for the study if they had intermittent claudication (Rutherford category 2/3) of the lower extremities caused by de novo or restenotic lesions of the superficial femoral artery or popliteal artery that were amenable to endovascular intervention. Target lesions were classified as TransAtlantic Inter-Society Consensus (TASC) class A, B, or C stenoses or occlusions (12) with a percent diameter stenosis of at least 50%, lesion length no greater than 10 cm, and at least one vessel runoff to the foot. Tandem lesions were included in the study provided they were located within the maximum specified treatment length of 10 cm. Patients with recent myocardial infarction or stroke and those with serum creatinine levels greater than 2.5 mg/dl were excluded from the study. Additionally, patients with rest pain, ischemic foot ulceration, or in-stent restenotic lesions were not eligible for enrollment. The study protocol received institutional review board approval at all enrolling centers and informed consent was obtained from all patients. Technique All patients who met the enrollment criteria of the study underwent a baseline clinical examination, resting ankle-brachial index (ABI) measurement, and lower-extremity arterial duplex ultrasound (US) examination. Before intervention, all patients were administered 325 mg of aspirin, clopidogrel (75 mg daily for 4 days before intervention or 300-mg preprocedural loading dose), and intravenous heparin or bivalirudin to maintain an activated clotting time greater than 200 seconds. Angiography was performed with use of conventional methods to identify the target lesion and confirm its suitability for the trial. The intent of the study was to conduct cryoplasty as a stand-alone therapy, reserving stent placement as a bailout procedure for suboptimal results, and adjunct angioplasty at the discretion of the investigator. Cryoplasty was performed with use of standard interventional technique with a inch angioplasty wire through a 7-F arterial sheath. When the lesion was identified, cryoplasty was performed with the PolarCath cryoplasty system (Cryovascular Systems, Los Gatos, CA). The components of the system include a cryoplasty catheter, a microprocessor-based inflation unit, and a nitrous oxide cylinder (Fig 1). The system is based on traditional balloon angioplasty technology but has been modified to incorporate nitrous oxide as the inflation medium Figure 1. The three components of the cryoplasty system consist of a cryoplasty catheter, a microprocessor-controlled inflation unit, and a nitrous oxide cylinder. instead of the standard mixture of saline solution and contrast medium. On initiation of cryoplasty, pressurized liquid nitrous oxide is delivered via a hypotube to a balloon reservoir at the distal end of the catheter. As the liquid nitrous oxide enters the balloon, it undergoes a phase shift to a gaseous form, which causes expansion and a dilation force of 8 atm. This phase change causes an endothermic reaction that simultaneously creates a heat sink that reduces the temperature at the interface of the balloon and the vessel wall to 10 C. The treatment cycle of simultaneous dilation and cooling lasts 20 seconds, and after passive warming of the catheter by body temperature and surrounding blood flow, the balloon is manually deflated and can be repositioned or removed. After cryoplasty, patients received clopidogrel for 30 days and were encouraged to take aspirin indefinitely. Postprocedural examinations included an ABI measurement within 24 hours and a lower-extremity arterial duplex scan within 7 days of cryoplasty. At 3 and 9 months, patients returned for clinical assessment, ABI measurement, and arterial duplex US. All US images were obtained by the local site personnel in accordance with instructions by an independent duplex US core laboratory (Vascular Ultrasound Core Laboratory, Boston, MA). Arterial Duplex Imaging Protocol All sites considered for entry into the trial were surveyed by the core laboratory to determine the available
3 Volume 16 Number 8 Laird et al 1069 equipment, personnel, and site experience in performing lower-extremity arterial duplex US. When these surveys had been reviewed, sites determined to have adequate experience were then required to submit two consecutive representative duplex US examinations of the infrainguinal arteries. The core laboratory subsequently recommended to the sponsor one of three actions based on review of these qualifying US studies: acceptance; requirement of further training; or rejection. For those centers requiring further training, representatives of the core laboratory went to the sites and provided hands-on training on their equipment. Subsequent to this training, two consecutive infrainguinal arterial duplex US examinations were submitted to the core laboratory. Review of these studies resulted in acceptance into or rejection from the trial. All images were recorded on super-vhs videotape. The core laboratory provided a study protocol for acquisition of the studies. The protocol described in detail appropriate duplex US technique, including grayscale image optimization, angle correction, sample volume size, pulse repetition frequency, and Doppler velocity measurements. All images were annotated according to the core laboratory protocol and all images were independently interpreted by the core laboratory technology staff. Interobserver variability was monitored with use of an internal standard operating procedure developed by the core laboratory. Study Endpoints The primary endpoints of the study were acute technical success of the cryoplasty procedure and clinical patency at 9 months. The technical success of stand-alone cryoplasty was defined as the ability to cross and dilate the target lesion with no greater than 30% residual angiographic stenosis and less than 50% residual narrowing by arterial duplex imaging (performed no more than 7 days after cryoplasty). Overall procedural success was defined in the same manner but included the results after adjunct stenting. Dissection was graded using the National Heart, Lung, and Blood Institute scale and significant dissection was defined by a grade of C or greater (13). Clinical patency was defined as freedom from target lesion revascularization within the study period. Secondary endpoints included device-related serious adverse events and maintenance of blood flow as assessed by ABI and duplex US. Serious adverse events were defined as any clinical event that was fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization. Blood flow assessment with ABI and duplex US data were all managed by the independent core laboratory. Peak systolic velocity (PSV) and systolic velocity ratios (SVRs) were recorded for all patients according to accepted criteria (14). Primary patency was determined with use of duplex US whereby restenosis was defined by a SVR greater than 2.0 at the target lesion measured at 9 months (15,16). Statistical Analysis The primary endpoints of the study were analyzed on an intent-to-treat basis. Quantitative variables were expressed with simple statistical methods for all group and subgroup patient characteristics. Differences in pre- and postinterventional ABI and angiographic percent diameter stenosis were considered significant at a level of P.05 according to the paired t test. Survival from target lesion revascularization was calculated with the Kaplan-Meier estimate. RESULTS Table 1 Baseline Lesion Characteristics (N 102) Characteristic Value Target lesion location (%) Superficial femoral artery 84.3 Popliteal artery 13.7 Combined 2.0 Angiographic measurements Reference vessel diameter (mm) Diameter stenosis (%) Total occlusions (%) 14.7 Lesion length (cm) Runoff vessels TASC Distribution (%) A(n 35) 34.3 B(n 26) 25.5 C(n 41) 40.2 A total of 102 patients consented and enrolled in the study between November 2001 and December 2002 at 16 institutions (15 in the United States and one in Europe). We treated 61 men and 41 women with an average age of 71 years 9. Cardiovascular risk factors included diabetes mellitus in 31%, hypertension in 87%, hyperlipidemia in 81%, and a history of tobacco use in 73%. During the course of the trial, two patients died of causes unrelated to the endovascular procedure (squamous cell lung carcinoma and multiple-organ failure with pneumonia). A total of 90 of the remaining 100 patients completed the intended clinical follow-up and their target lesion revascularization data are reported herein. The duplex imaging data represent scans received for 82 patients, of which the core laboratory determined that 77 (94%) were of adequate quality for independent interpretation. Baseline lesion characteristics are listed in Table 1. The majority of the lesions were located in the superficial femoral artery, and the patients treated typically had one or two tibioperoneal runoff vessels. The stenoses were complex, as evidenced by the percentage of occlusions and TASC class C lesions treated. The acute and midterm outcomes with cryoplasty are reported in Table 2. ABIs improved from a baseline of to at 3 months and were well-maintained at at 9 months (P.05, 3 months and 9 months vs baseline). Subjective improvement in claudication was observed in 75% of patients at 3 months and in 89% at 9 months. Angiographic examples of TASC A, B, and C lesions and their acute outcomes after cryoplasty are depicted in Figures 2, 3, and 4, respectively. The clinical patency rate in the 90 patients who completed follow-up was 82.2%, as only 16 patients required repeat revascularization during the study period. The duplex imaging driven primary patency rate at 9 months was 70.1%, as imaging identified 23 patients with an SVR greater than 2.0. The technical and procedural suc-
4 1070 Femoropopliteal Cryoplasty: Multicenter Midterm Results August 2005 JVIR Table 2 Acute and Midterm Cryoplasty Results Value Outcome (%) Procedural success 94.1 Technical success 85.3 Dissection rate 6.9 Bail-out stent rate 8.8 Residual diameter stenosis 11 11* Target lesion 17.8 revascularization TASC A (n 35) 11.4 TASC B (n 26) 15.4 TASC C (n 41) Month clinical patency Month primary patency 70.1 * P.05 versus baseline. Figure 2. (a) Baseline angiogram of a TASC class A lesion in an elderly male patient with a critical stenosis of the mid-popliteal artery directly located behind the knee joint. (b) Final angiogram after cryoplasty demonstrates optimal vessel dilation without dissection in a location that is ideally treated without the need for stent placement. cess of 32 diabetic patients in the study was similar to that of nondiabetic patients (84.4% and 96.9%, respectively). At 9 months, 89% of diabetic patients noted improvement in their claudication and 80% had sustained improvement in their ABI. The primary clinical patency rate at 9 months in this subset of patients was 88.9%. A total of 15 patients in the study presented with target vessels that were occluded. The technical success rate in this group was 67% and the procedural success rate was 100%, as five patients underwent adjunct stent implantation for suboptimal cryoplasty. At 9 months, all patients in this subgroup reported improvement in claudication symptoms, and 89% had sustained improvement in their ABI. The primary clinical patency rate in patients with occlusions was 92.3%. The investigators in the study performed stent implantation after cryoplasty in a total of only nine patients. None of these patients required revascularization during the trial, and all exhibited sustained improvement in ABI. Throughout the study enrollment, there were no unanticipated adverse events associated with the use of the cryoplasty device. Other adverse events included seven patients who experienced minor vascular access complications and two patients who required prolonged hospitalization (for hypotension and hyperthyroidism, respectively). Five patients underwent target vessel revascularization at sites remote to the target lesion. Eleven patients had endovascular procedures performed in vessels other than the target vessel, and seven patients required coronary revascularization. DISCUSSION Endovascular treatment of femoropopliteal lesions has long been hindered by suboptimal patency rates. Conventional angioplasty in particular has been limited by high dissection rates and vascular recoil. Despite technical balloon modifications and variations in technique, there has been little progress in defeating the process of restenosis. The current study demonstrated a high degree of technical success in a broad selection of femoropopliteal lesions with use of cryoplasty. In addition, clinical patency rates with use of this new form of endovascular cryotherapy were favorable in comparison with historical angioplasty outcomes. Angioplasty of femoropopliteal lesions traditionally has achieved technical and hemodynamic success in 50% 75% of cases (17). Significant dissection rates in contemporary studies of angioplasty have been reported to occur at a higher frequency than observed in our cohort (2). The technical success rate seen with cryoplasty in this trial was 85.3%, and significant dissection was seen in only 6.9% of patients treated. The apparent improvement in acute outcomes demonstrated with cryoplasty may in part explain the low rate of target lesion revascularization seen in this trial. Conventional angioplasty in a broad subset of lesions has been shown to have a patency rate of 59% at 1 year (3), whereas cryoplasty resulted in a 9-month clinical patency rate of 82% and a primary patency rate of 70%. These findings are consistent with previously reported outcomes of femoropopliteal cryoplasty in which the 18-
5 Volume 16 Number 8 Laird et al 1071 Figure 3. (a) Baseline angiogram of a TASC class B lesion in a patient with a chronic occlusion of the proximal left popliteal artery. (b) Final angiogram after stand-alone cryoplasty demonstrates a smooth-bordered acute outcome that is free of dissection. month angiographic patency rate was found to be 83% (18). This study used duplex US and target lesion revascularization to determine the patency of femoropopliteal arteries after cryoplasty. Duplex US has demonstrated reliable efficacy in determining significant stenosis (19 21), and as a method of objectively demonstrating binary restenosis ( 50%), duplex US is highly accurate. However, in clinical practice, a SVR of 2.0 alone is often associated with few or no symptoms. As a result, criteria that incorporate maximum values of PSV have been developed ( 250 cm/ sec) in an effort to further refine the clinical application of duplex US in this setting (22). In the current study, only eight of the 23 patients with SVRs greater than 2.0 had a PSV greater than 250 cm/sec. Whereas some investigators have defined restenosis with SVR values greater than 2.5 and others have suggested that a SVR of at least 3.0 is potentially more accurate (15), we elected to use a more conservative measure of patency. The limitations of conventional angioplasty in the superficial femoral artery and popliteal arteries have led to increasing use of stents in an effort to achieve better outcomes. Newer stent designs and materials continue to be evaluated. Two studies have reported clinical and primary patency rates of approximately 80% at 9 12 months with use of a nitinol coil stent design (23,24). The lesions treated in these studies were typically shorter and less complex than those reported herein. Successful treatment of more complex lesions with resultant patency rates of approximately 80% have alternatively been reported with use of stent-grafts (25,26). However, despite widespread use of stents, long-term patency rates are still in the range of 60% 70% at 1 year (27 29) and meaningful clinical trial data are lacking. The aggressive neointimal response to stent implantation is well-understood, and newer problems such as stent strut fractures (30) and inflammatory reactions to endografts (31) have been reported. In our study, cryoplasty required bailout stent implantation in only 8.8% of cases. Interestingly, none of the patients who received stents experienced restenosis, and all had sustained improvement in ABI. Albeit small in numbers, this experience raises the notion that cryoplasty may have a favorable impact in limiting the proliferative response to stents. Several potential mechanisms of action, singularly or in concert, may have contributed to the cryoplasty results demonstrated in this study. The degree of vascular injury and dissection seen after angioplasty has been strongly linked to restenosis (32). It stands to reason that a more benign method for achieving vessel dilation would therefore be accompanied by less reactivity. By inducing a phase change (solidification) in the interstitial fluids of the artery, cryoplasty may modify the mechanical properties of the plaque and vessel wall in a manner that promotes a more homogeneous response to vessel dilation. As a result, cryoplasty may be more likely to produce smaller and more evenly distributed fissures in the plaque and vessel wall. The low rate of significant dissection seen in the trial grossly supports this concept. Angioplasty outcomes are also affected by vascular recoil. Elastic recoil after standard angioplasty depends on the density of elastin in the target artery as well as the condition of the elastin fibers (33). Femoropopliteal arteries contain a high concentration of elastin fibers relative to other commonly treated vascular targets. Cryotherapy, by virtue of the formation and expansion of ice within the fibrous structure of the arterial wall, causes a transient deformation of elastin fibers and uncoiling of elastin layers (9,34). These acute changes reduce the elasticity of the arterial wall at the site of cryotherapy and may thereby limit vascular recoil after cryoplasty. The long-term benefits of cryoplasty as it pertains to patency outcomes may be related to apoptosis of SMCs and positive remodeling. Neointimal hyperplasia results from the migration, signaling, and proliferation of SMCs into the subintima at the site of balloon dilation (35). The frequency of apoptosis is lower in restenotic lesions, suggesting that decreases in apoptosis contribute to neointimal formation by prolonging the lifespan of SMCs (36). Earlier research has documented that SMCs are inherently sus-
6 1072 Femoropopliteal Cryoplasty: Multicenter Midterm Results August 2005 JVIR Figure 4. (a) Baseline angiogram of a TASC class C lesion in a patient with a long segment of occlusion involving the right femoropopliteal junction. (b) Final angiogram after cryoplasty demonstrates acute angiographic success with limited mild dissection and improved distal flow. ceptible to cold thermal energy and specifically can be induced into an apoptotic life cycle (10,37). At the operating temperature of cryoplasty ( 10 C), in vitro studies have shown that nearly half the SMC population present will undergo programmed cell death (38). By inducing apoptosis and thereby reducing the population of SMCs in the target vessel, cryotherapy may inhibit neointimal formation. In the current study, the mean PSV of patients with an SVR of at least 2.0 was found to decrease significantly at the treatment site from 3 months to 9 months, further supporting the mechanism of apoptosis and positive remodeling after cryoplasty. This reduction in stenosis severity is unusual after femoropopliteal intervention, in which setting the expected outcome is progression over time. Positive remodeling as a mechanism for preserving arterial lumen dimensions in the presence of atheroma has been well-documented (39). Arterial collagen content is significantly lower in arteries that demonstrate positive remodeling compared with those with constrictive remodeling (40). In addition, cellular apoptosis in the neointima and media is favorably correlated with positive remodeling after balloon angioplasty. As vascular SMCs produce collagen, their depletion via apoptosis leads to decreased collagen synthesis. Therefore, by inducing SMC apoptosis, cryoplasty may reduce the synthesis of new collagen and suppress negative arterial remodeling. However, because the original collagen matrix is not disrupted by cryotherapy, vessel integrity is maintained. The current study was a prospective multicenter registry that did not seek to randomize versus conventional angioplasty or stent implantation. Direct comparisons between these groups are therefore limited to historical references in the literature. Outcomes for femoropopliteal arterial interventions vary considerably based on patient and lesion characteristics, and therefore these data cannot be extrapolated to potential outcomes in lesions greater than 10 cm in length or in patients with critical limb ischemia. Nonetheless, we studied a wide variety of lesions with reasonable complexity and the results compare favorably with known outcomes of conventional angioplasty and stent implantation. By virtue of the 9-month primary endpoint, these data represent midterm results, and long-term follow-up will be necessary to properly evaluate the enduring impact of cryoplasty. Cryoplasty represents a safe and effective method of treatment for arterial lesions in the superficial femoral and popliteal arteries. The ability to successfully treat femoropopliteal lesions with limited need for stent implantation is clinically desirable. The capacity to alter the expected biologic response to percutaneous intervention represents a potential improvement in endovascular outcomes. Acknowledgments: The authors would like to acknowledge the participation of the following physicians who contributed to the completion of the trial enrollment: Frederick St. Goar, MD (El Camino Hospital, Mountain View, CA); James Hermiller, MD (St. Vincent s Hospital, Indianapolis, IN); Anthony Sintetos, MD, PhD (Salinas Valley Memorial Hospital, Salinas, CA); Christopher White, MD (Ochsner Clinic, New Orleans, LA); Roger Gammon, MD (Austin Heart Institute, Austin, TX), James Zidar, MD (Duke University Medical Center, Durham, NC); Gregg Alzate, MD (Sharp Memorial Hospital, San Diego, CA); William Edwards, Jr, MD (St. Thomas Hospital, Nashville, TN); Tony Das, MD (Presbyterian Hospital, Dallas, TX); Richard Heuser, MD (St. Luke s Medical Center, Phoenix, AZ); Robert Safian, MD (William Beaumont Hospital, Royal Oak, MI); Barry Katzen, MD (Miami Cardiac & Vascular Institute, Miami, FL); and James Margolis, MD (Mt. Sinai Medical Center, Miami Beach, FL). References 1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique
7 Volume 16 Number 8 Laird et al 1073 and a preliminary report of its application. Circulation 1964; 30: Zorger N, Manke C, Lenhart M et al. Peripheral arterial balloon angioplasty: effect of short versus long balloon inflation times on morphologic results. J Vasc Interv Radiol 2002; 13: Kandarpa K, Becker GJ, Hunink MG, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001; 12: Nakatani M, Takeyama Y, Shibata M, et al. Mechanism of restenosis after coronary intervention: differences between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003; 12: Hayerizadeh BF, Zeller T, Krankenberg H, Scheinert D, Biamino G. Superficial femoral artery stenting using nitinol stents-a German multicenter experience. J Invas Cardiol 2004; 16:12A 14A. 6. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol 2004; 7: Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: metaanalysis. Radiology 2001; 22: Ansel GM, Botti CF Jr, George BS, Kazienko BT. Clinical results for the training-phase roll-in patients in the Intracoil femoropopliteal stent trial. Cathet Cardiovasc Intervent 2002; 56: Gage A, Fazekas G, Riley E. Freezing injury to large blood vessels in dogs. Surgery 1967; 61: Soloff BL, Nagle WA, Moss AJ Jr, Henle KJ, Crawford JT. Apoptosis induced by cold shock in vitro is dependent on cell growth phase. Biochem Biophys Res Commun 1987; 145: Fava M. Femoropopliteal cryoplasty: long-term results of first in man experience. Presented at the 28th Annual Meeting of the Society of Interventional Radiology; March 23, 2003; Salt Lake City, UT. 12. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. Trans- Atlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31(suppl): S1 S Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary dissection. Am J Cardiol 1991; 68: Kohler TR, Andros G, Porter JM, et al. Can duplex scanning replace arteriography for lower extremity arterial disease? Ann Vasc Surg 1990; 4: Strandness DE Jr. Peripheral arterial system. In: Duplex scanning in vascular disorders 2nd ed. New York: Raven Press, 1993; Leng G, Whyman MR, Donnan PT, et al. Accuracy and reproducibility of duplex ultrasonography in grading femoropopliteal stenoses. J Vasc Surg 1993; 17: Milford MA, Weaver FA, Ludell CJ, Yellin AE. Femoropopliteal percutaneous transluminal angioplasty for limb salvage. J Vasc Surg 1998; 8: Fava M, Loyola S, Polydorou A, et al. Cryoplasty for femoropopliteal arterial disease: late angiographic results of initial human experience. J Vasc Interv Radiol 2004; 15: Fletcher JP, Kershaw LZ, Chan A, et al. Noninvasive imaging of the superficial femoral artery using ultrasound duplex scanning. J Cardiol Surg 1990; 31: Whyman MR, Gillespie I, Ruckley CV, et al. Screening patients with claudication form femoropopliteal disease before angioplasty using Doppler color flow imaging. Br J Surg 1992; 79: Kohler TR, Nance DR, Cramer MM, et al. Duplex scanning for diagnosis of aortoiliac and femoropopliteal disease: a prospectrive study. Circulation 1987; 76: Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: Jahnke T, Voshage G, Muller-Hulsbeck S, et al. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002; 13: Ansel GM, Botti CF Jr, George BS, et al. Clinical results for the training-phase roll-in patients in the Intracoil femoralpopliteal stent trial. Cathet Cardiovasc Interv 2002; 56: Saxon RR, Coffman JM, Gooding JM, et al. Long-term results of the eptfe stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol 2003; 14: Jahnke T, Andresen R, Muller-Hulsbeck S, et al. Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: midterm results of a prospective trial. J Vasc Interv Radiol 2003; 14: Zollikofer CL, Antonucci F, Pfyffer M, et al. Arterial stent placement with use of the Wallstent: midterm results of clinical experience. Radiology 1991; 179: Do DD, Triller J, Walpoth BH, et al. A comparison study of self-expandable stents versus balloon angioplasty alone in femoropopliteal artery occlusions. Cardiovasc Intervent Radiol 1992; 15: Saproval MR, Long AL, Raynaud AC, Beyssen BM, Fiessinger JN, Gaux JC. Femoropopliteal stent placement: longterm results. Radiology 1992; 184: Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six month results. Circulation 2002; 106: Hayoz D, Do DD, Mahler F, Triller J, Spertini F. Acute inflammatory reaction associated with endoluminal bypass grafts. J Endovasc Surg 1997; 4: Wilensky RL, March KL, Gradius-Pizlo I, Sandusky G, Fineberg N, Hathatway DR. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 1995; 92: Gardiner GA, Bonn J, Sullivan KL. Quantification of elastic recoil after balloon angioplasty in the iliac arteries. J Vasc Interv Radiol 2001; 12: Mandeville AF, McCabe BF. Some observations on the cryobiology of blood vessels. Laryngoscope 1967; 77: Schwartz RS. The vessel wall reaction in restenosis. Semin Intervent Cardiol 1997; 2: Bauriedel G, Schluckebier S, Hutter R, et al. Apoptosis in restenosis versus stable angina atherosclerosis: implications for the pathogenesis of restenosis. Arterioscler Thromb Vasc Biol 1998; 18: Durand E, Mallat Z, Addad F, et al. Time courses of apoptosis and cell proliferation and their relationship to arterial remodeling and restenosis after angioplasty in an atherosclerotic rabbit model. J Am Coll Cardiol 2002; 39: Joye J. New technologies for femoropopliteal treatment. Presented at The Paris Course on Revascularization; May 25, 2003; Paris, France. 39. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: Lafont A, Durand E, Samuel JL, et al. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation 1999; 100:
Cryoplasty for the Treatment of Femoropopliteal Arterial Disease: Extended Follow-up Results
II-52 J ENDOVASC THER CLINICAL INVESTIGATION Cryoplasty for the Treatment of Femoropopliteal Arterial Disease: Extended Follow-up Results John R. Laird, MD 1 ; Giancarlo Biamino, MD 2 ; Thomas McNamara,
More informationLessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?
Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention? Michael Wholey, MD, MBA San Antonio, TX USA 19/06/2009 at 09:35 during 4mn as a Speaker Session: Improving Femoral Artery Recanalization
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationTreating In-Stent Restenosis with Brachytherapy: Does it Actually Work?
Treating In-Stent Restenosis with Brachytherapy: Does it Actually Work? Matthew T. Menard, M.D. Brigham and Women s Hospital Pacific Northwest Endovascular Conference June 15, 2018 DISCLOSURE Matthew Menard,
More informationCryoplasty versus conventional angioplasty in peripheral arterial disease: 3 year analysis of reintervention free survival by treatment received.
Cryoplasty versus conventional angioplasty in peripheral arterial disease: 3 year analysis of reintervention free survival by treatment received. Poster No.: C-0343 Congress: ECR 2011 Type: Scientific
More informationBrachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts
Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts Disclosure Speaker name: Matthew T. Menard... x I do not have
More informationPoor outcomes with cryoplasty for lower extremity arterial occlusive disease
From the Society for Clinical Vascular Surgery Poor outcomes with cryoplasty for lower extremity arterial occlusive disease Gregory C. Schmieder, MD, Megan Carroll, BA, BS, and Jean M. Panneton, MD, Norfolk,
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationThe Final Triumph Of Endovascular Therapy In SFA Treatment
The Final Triumph Of Endovascular Therapy In SFA Treatment MEET 07 Mark W. Mewissen, M.D. Director, St Lukes Vascular Center Milwaukee, WI Endovascular Therapy In SFA Treatment: Works In Progress! Mark
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationA Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention
A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationNew Data to Shape the Era of Drug Elution in Peripheral Interventions
New Data to Shape the Era of Drug Elution in Peripheral Interventions William A. Gray MD Director of Endovascular Services Columbia University Medical Center New York Lower Extremity Endovascular - Interventions
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationThe incidence of peripheral artery disease (PAD)
Pharmacologic Options for Treating Restenosis The role of cilostazol in the treatment of patients with infrainguinal lesions. By Osamu Iida, MD, and Yoshimitsu Soga, MD The incidence of peripheral artery
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationPlaque Excision Infrainguinal PAD An update on this nonstenting alternative, with intermediate-term results of the ongoing TALON Registry.
Plaque Excision Treatment of Infrainguinal PAD An update on this nonstenting alternative, with intermediate-term results of the ongoing TALON Registry. BY ROGER GAMMON, MD Despite surgical options and
More informationUtility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography
Utility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography Jon C. George, MD; Vincent Varghese, DO From the Deborah Heart and Lung Center, Browns Mills, New Jersey. ABSTRACT:
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationTHE NEW ARMENIAN MEDICAL JOURNAL
THE NEW ARMENIAN MEDICAL JOURNAL Vol.10 (2016), Nо 1, p. 57-62 Clinical Research SHORT-TERM OUTCOMES OF ENDOVASCULAR INTERVENTION OF INFRAINGUINAL ARTERIES IN PATIENTS WITH CRITICAL LIMB ISCHEMIA Sultanyan
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationThe Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System
The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System A prospective, multicenter, non randomized study to evaluate the safety and efficacy of the Medtronic AVE Driver Coronary Stent
More information2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
More informationClinical and morphological features of patients who underwent endovascular interventions for lower extremity arterial occlusive diseases
Original paper Clinical and morphological features of patients who underwent endovascular interventions for lower extremity arterial occlusive diseases Sakir Arslan, Isa Oner Yuksel, Erkan Koklu, Goksel
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationJohn E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationMICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together
DRUG-COATED BALL0ON TREATMENT FOR PATIENTS WITH INTERMITTENT CLAUDICATION: INSIGHTS FROM THE IN.PACT GLOBAL FULL CLINICAL COHORT MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES Medtronic Further. Together
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationDierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
More informationAccurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery
Accurate Vessel Sizing Drives Clinical Results IVUS In the Periphery Discussion Iida O, et. al. Study Efficacy of Intravascular Ultrasound in Femoropopliteal Stenting for Peripheral Artery Disease With
More informationRobert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
More informationTurbo-Power. Laser atherectomy catheter. The standard. for ISR
Turbo-Power Laser atherectomy catheter The standard for ISR Vaporize the ISR challenge In-stent restenosis (ISR) Chance of recurring 7 115,000 + /year (U.S.) 1-6 Repeated narrowing of the arteries after
More informationThe Utility of Atherectomy and the Jetstream Atherectomy System
The Utility of Atherectomy and the Jetstream Atherectomy System William A. Gray, MD Columbia University Medical Center 2014 Boston Scientific Corporation or its affiliates. All rights reserved. IMPORTANT
More informationLatest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
More informationPAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014 Van Crisco, MD, FACC, FSCAI First Coast Heart and Vascular Center, PLLC Jacksonville, FL 678-313-6695 Conflict of Interest Bayer Healthcare
More informationInitial Clinical Experience with a Novel Dedicated Cobalt Chromium Stent for the Treatment of Below-the-knee Arterial Disease
Initial Clinical Experience with a Novel Dedicated Cobalt Chromium Stent for the Treatment of Below-the-knee Arterial Disease a report by Angelo Cioppa, Luigi Salemme, Vittorio Ambrosini, Giovanni Sorropago,
More informationDISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.
DISRUPT PAD (( Data Summary )) DISRUPT PAD Data Summary SPL 60971 Rev. B 1 Summary of the key findings from the DISRUPT PAD Study 99% of femoropopliteal lesions treated were moderately or severely calcified.
More informationVessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
More informationBTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration
BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration M Sapoval, C Del Giudice, C Dean Interventional Radiology Dep Hôpital Européen Georges Pompidou APHP, Paris, France IMPORTANT
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationMEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?
MEET 2009 SFA stenting in 2009 : The good and the ugly What factors influence patency? M. Bosiers K. Deloose P. Peeters 1 TASC II 2007 vs TASC 2000 Type A Type B Type C Type D 2000 < 3 cm 3-5 cm < 3 cm
More informationVascular Medicine. Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional Stenting
Vascular Medicine Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional Stenting Martin Schillinger, MD; Schila Sabeti, MD; Petra Dick, MD; Jasmin
More informationUse of Laser In BTK Disease (CLI)
Use of Laser In BTK Disease (CLI) Click to edit academic affiliation, practice or hospital logo(s) of preference. Product and/or sponsor logos not permitted, per CME guidelines. Richard Kovach, MD, FACC,
More informationPaclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment
Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment HEALTH QUALITY ONTARIO NOVEMBER 2015 Ontario Health Technology Assessment Series; Vol. 15: No. 20, pp. 1 62,
More informationCOMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
More informationEvolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data
Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden Hospital Charité, CC11 Academic Teaching Hospitals
More information9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge
Disclosures State-of-the-Art Endovascular Lower Extremity Revascularization Promotional Speaker Jansen Pharmaceutical Promotional Speaker Amgen Pharmaceutical C. Michael Brown, MD, FACC al Cardiology Associate
More informationLIFESTREAM TM First look at the BOLSTER 2-year follow up data
LIFESTREAM TM First look at the BOLSTER 2-year follow up data Dierk Scheinert, MD, on behalf of the Investigators Department of Angiology University Hospital Leipzig, Germany Disclosure Dierk Scheinert,
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More informationDrug- Coated Balloons for the SFA: Overview of Technology and Results
Drug- Coated Balloons for the SFA: Overview of Technology and Results NCVH Latin American 2015 Bogota, Colombia April 9-11, 2015 Brian G. DeRubertis, M.D. Associate Professor of Surgery Division of Vascular
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationSuperficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA
: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA Peripheral arterial disease (PAD) of the superficial femoral artery (SFA) is the most common cause of intermittent claudication
More informationImaging Strategy For Claudication
Who are the Debators? Imaging Strategy For Claudication Duplex Ultrasound Alone is Adequate to Select Patients for Endovascular Intervention - Pro: Dennis Bandyk MD No Disclosures PRO - Vascular Surgeon
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ABI. See Ankle-brachial index (ABI). Afterload, deconstructing of, in ventricular vascular interaction in heart failure, 449 Air plethysmography
More informationOn behalf of the DURABILITY Investigators:
On behalf of the DURABILITY Investigators: S. Müller-Hülsbeck 1, M. Bosiers 2, G. Torsello 3, D. Scheinert 4, H. Gissler 5, J. Ruef 6, T. Jahnke 7, P. Peeters 8, K. Daenens 9, J. Lammer 1 1 Ev.-Luth. Diakonissenanstalt
More informationStudy of a Balloon-Expandable Covered Stent for Obstructive Lesions in the Iliac Artery
Study of a Balloon-Expandable Covered Stent for Obstructive Lesions in the Iliac Artery First Look at the 24-Month Results of the BOLSTER Trial John R. Laird, MD, on behalf of the Investigators Adventist
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationThe essentials for BTK procedures: wires, balloons, what else
A comprehensive approach to diabetic patient Tx The essentials for BTK procedures: wires, balloons, what else Dai-Do Do Clinical and Interventional Angiology Cardiovascular Department Disclosure Speaker
More informationResults of a European Multicentre Iliac Stent Trial with a Flexible Balloon Expandable Stent
Eur J Vasc Endovasc Surg 24, 511±515 (2002) doi:10.1053/ejvs.2002.1775, available online at http://www.idealibrary.com on Results of a European Multicentre Iliac Stent Trial with a Flexible Balloon Expandable
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationEfficacy of Cilostazol After Endovascular Therapy for Femoropopliteal Artery Disease in Patients With Intermittent Claudication
Journal of the American College of Cardiology Vol. 53, No. 1, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.020
More informationSponsored by Boston Scientific Corporation. February 2010
Supplement to Sponsored by Boston Scientific Corporation February 2010 CONTENTS 3 CryoPlasty Therapy for the Infrainguinal Arteries CryoPlasty Therapy offers a unique solution for treating this challenging
More informationUpdate on the Ranger clinical trial programme
Update on the Ranger clinical trial programme Dierk Scheinert, MD Universitätsklinikum Leipzig, Leipzig, Germany on behalf of the RANGER SFA investigators Disclosure Speaker s name: Dierk Scheinert I have
More informationPaclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis
Paclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis T. Hölzenbein, A. Ugurluoglu, M. Aspalter, W. Hitzl, K. Linni Dep Vascular & Endovascular Surgery
More informationMichael K.W. Lichtenberg, MD
Ranger All-Comer Registry Treatment of femoropopliteal atherosclerotic lesions using the Drug eluting Balloon Ranger: An All Comers Registry Michael K.W. Lichtenberg, MD Klinikum Arnsberg Arnsberg, Germany
More informationHybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results.
Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results. Wronski J. 1), 2) 3), Wilczynski M 1), Gembal P 1), Milik K 1), Dec St 1), Grybos
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationAlternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
More informationEndovascular and Hybrid Treatment of TASC C & D Aortoiliac Occlusive Disease
Endovascular and Hybrid Treatment of TASC C & D Aortoiliac Occlusive Disease Arash Bornak, MD FACS Vascular & Endovascular Surgery University of Miami Miller School of Medicine No disclosure BACKGROUND
More informationDisclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA
In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA Disclosures No financial disclosures. Cameron M. Akbari, MD, MBA, FACS Site Director, Vascular Surgery Medstar
More informationPeripheral Arterial Disease: the growing role of endovascular management
Peripheral Arterial Disease: the growing role of endovascular management Poster No.: C-1931 Congress: ECR 2012 Type: Educational Exhibit Authors: E. M. C. Guedes Pinto, E. Rosado, D. Penha, P. Cabral,
More informationIncreased Flexibility of AneuRx Stent-Graft Reduces Need for Secondary Intervention Following Endovascular Aneurysm Repair
583 Increased Flexibility of AneuRx Stent-Graft Reduces Need for Secondary Intervention Following Endovascular Aneurysm Repair Frank R. Arko, MD; W. Anthony Lee, MD; Bradley B. Hill, MD; Paul Cipriano,
More informationEndovascular treatment (EVT) has markedly advanced,
Ann Vasc Dis Vol. 6, No. 3; 2013; pp 573 577 Online August 12, 2013 2013 Annals of Vascular Diseases doi:10.3400/avd.oa.13-00055 Original Article A Review of Surgically Treated Patients with Obstruction
More informationThere are multiple endovascular options for treatment
Peripheral Rotablator Atherectomy: The Below-the-Knee Approach to Address Calcium Head On Peripheral Rotablator s front-cutting, diamond-tipped burr provides stable rotation in calcified lesions. BY SONYA
More informationPractical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
More informationShockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany
Shockwave Medical Lithoplasty Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany Disclosure Speaker name: Thomas Zeller, MD I have the following potential conflicts of interest
More informationStep by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery
Step by step Hybrid procedures in peripheral obstructive disease Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name: H.H. Staab I have the following
More informationCLI Treatment Using Long and Scoring Balloons
CLI Treatment Using Long and Scoring Balloons Robert Beasley, MD Director of Vascular and Interven3onal Radiology Mount Sinai Medical Center Miami Beach, FL Disclosures Consultant/Advisory Board: Abbott
More informationUtility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery
Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery Yoshimitsu Soga, MD, a Osamu Iida, MD, b Keisuke Hirano, MD,
More informationMichael K. W. Lichtenberg MD, FESC on behalf of KANSHAS 1 investigators; Tepe G, Müller-Hülsbeck S, Deloose K, Verbist J, Goverde P, Zeller T
Interim 30-day analysis from the KANSHAS 1 study of the novel KANSHAS drug coated balloon for treatment of femoropopliteal occlusive disease; a latest first-in-human study Michael K. W. Lichtenberg MD,
More informationDisclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?
Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long? UCSF Vascular Symposium 2017 April 6-8, 2017 San Francisco, CA Disclosures Consulting, Speakers
More informationPHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS
PHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS PACLITAXEL VS RAPAMYCIN Paclitaxel essentially freezes the microtubules that are in place during cell division. The cells cannot complete cell division
More informationBioMimics 3D in my Clinical Practice
BioMimics 3D in my Clinical Practice M Lichtenberg M.D. Vascular Centre Arnsberg / German Venous Centre Arnsberg CAUTION: Investigational Device. Limited by Federal (or United States) Law to Investigational
More informationStratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI?
Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI? Peter F. Lawrence, M.D. Gonda Vascular Center Division of Vascular Surgery
More informationperipheral arterial disease; PAD endovascular therapy; EVT
15 603 610 2006 1 1 1 1 1 2 3 1 2 peripheral arterial disease; PAD endovascular therapy; EVT chronic total occlusion; CTO CTO TASC-C DEVT 1997 7 2006 4 PAD 171 218 EVTCTO60 61 51 9 70 8.6cm 8049 1 9 2
More informationRecommendations for Follow-up After Vascular Surgery Arterial Procedures SVS Practice Guidelines
Recommendations for Follow-up After Vascular Surgery Arterial Procedures 2018 SVS Practice Guidelines vsweb.org/svsguidelines About the guidelines Published in the July 2018 issue of Journal of Vascular
More information